ARTICLE BY BIO X CELL

Translational Continuity: Why Drug Programs Fail Early

Bio X Cell has recently published an article talking about why over 90% of drug candidates fail in clinical trials, often due to the inability of animal models to accurately predict human outcomes.

The Shift to Organoids

To address this “translational gap,” the FDA Modernization Act 2.0 now allows researchers to use New Approach Methodologies (NAMs), such as organoids. These 3D human-cell models capture the structural and functional features of native tissues, offering a more human-relevant alternative to traditional animal testing.

The Importance of Reagent Purity

While organoids are powerful tools, they are highly sensitive to trace contaminants found in standard reagents. Impurities in functional antibodies—such as endotoxins, preservatives, and stabilizers—can cause:

• Cellular stress and inflammation.
• Altered morphology and behavior.
• Misinterpreted results regarding a drug’s safety or efficacy.

Bio X Cell’s Ultrapure Solutions

Bio X Cell provides ultrapure functional antibodies specifically formulated for organoids and organ-on-chip systems. These reagents help safeguard research by:

• Minimizing Artifacts: Formulations are free of added proteins and preservatives.
• Ensuring Continuity: Using the same high-quality antibody across both in vitro organoids and in vivo models reduces variability.
• Targeting Key Pathways: The portfolio includes essential antibodies for immuno-oncology and autoimmune research, such as anti-PD-1 and anti-IFNγ.